Business Overview
2011
43
$80M
Series C
11
Founded in 2011, NovellusDX has brought together a team of skilled individuals from several fields, including synthetic biology, functional genomics, bioinformatics, engineering, algorithm development, clinical laboratory and healthcare commercialization. Together, they lead the companys mission to deliver evidence-based clinical insights and enable oncology professionals to treat every cancer and each patient with the precise treatment and to support pharmaceutical companies with their drugs life cycle.Genome sequencing techniques reveal mutations but provide no knowledge whether the translated protein is actually aberrantly activated. This is because the functional significance of most mutations is unknown, let alone that of networks of interacting proteins. NovellusDx leverages its live cell based assay to complement the power of NGS with actionable insights on the affected signaling pathways.
Founders (2)
| Name | Title | Contact | |
|---|---|---|---|
 | ㅤMichael Vidne | CEO | |
 | ㅤHaim Gil-Ad |
Board and Advisors (1)
| Name | Title | Contact | |
|---|---|---|---|
 | ㅤRoberto De Ponti | Head, Corporate N… | 1 |
Funding Rounds (0)
M&A Events (0)
Investors (11)
| Investor Name | Investor Type | AUM ($) | |
|---|---|---|---|
 | ㅤBio Capital Impact Fund | Venture Capital | 0 |
| ㅤCormorant Asset Management | Hedge Fund | 900,000,000 | |
 | ㅤHBM Healthcare Investments | Investment Firm | 0 |
 | ㅤHelsinn Investment Fund | Investment Firm | 0 |
 | ㅤIntercure | Company | 0 |
 | ㅤNovartis Venture Fund | Corporate Venture Capital | 800,000,000 |
 | ㅤOrbiMed | Venture Capital | 15,000,000,000 |
 | ㅤPontifax | Venture Capital | 600,000,000 |
 | ㅤSR One | Corporate Venture Capital | 1,000,000,000 |
 | ㅤWellington Management | Investment Firm | 0 |
 | ㅤWindham Venture Partners | Venture Capital | 0 |
Patents (6)
Research Publications (0)
Certifications (0)
AI Technology Stack
2
Utilizing advanced machine learning methods on a proprietary datasets of cell images, we learn and assign the functional significance to unknown mutations. Accurate prediction of the signaling pathway activity elicited by Variants of Uncertain Significance (VUS) and their drug sensitivity using Deep Convolutional Neural Networks on fluorescent microscopy images of cells.
News
Jobs (0)